• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌患者循环血管内皮生长因子及其可溶性受体sVEGFR-1

[Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer].

作者信息

Swidzińska Ewa, Ossolińska Maria, Naumnik Wojciech, Izycki Tomasz, Kucejko Wojciech, Chyczewska Elzbieta

机构信息

Kliniki Chorób Płuc i Gruźlicy AM w Białymstoku.

出版信息

Pneumonol Alergol Pol. 2004;72(9-10):389-94.

PMID:16021992
Abstract

Angiogenesis plays an important role in the pathogenesis of lung cancer. This process is caused by the imbalance between stimulating and inhibiting agents. VEGF is a key stimulator having a biologic effect via two different receptors of tyrosine kinase: VEGF-R1 and VEGF-R2. A soluble form of sVEGF-R1 is a negative regulator of VEGF activity. The serum concentrations of VEGF, sVEGF-R1 were assayed in 24 patients with NSCLC and 13 patients with SCLC and 10 healthy volunteers by means of ELISA method. The serum concentrations of VEGF were significantly higher in patients than in controls (p=0.016). The concentration of sVEGF-R1 was not significantly different in patients and controls. No statistically significant differences were established between the concentrations of VEGF, and sVEGF-R1 with regard to such clinical features, as: performance staging, clinical staging (stage III vs. stage IV) and histological pattern (NSCLC vs. SCLC). The significantly higher VEGF concentrations were reported in patients with the tumor of more than 7.5 cm in the diameter (p=0.027). Analyzing the influence of the response to treatment on the concentrations of parameters examined, a significant increase in VEGF concentration was demonstrated in the case of disease progression (p=0.034). The concentrations of sVEGF-R1 did not change after treatment. No correlation was found between parameters examined.

摘要

血管生成在肺癌发病机制中起重要作用。这一过程由刺激因子和抑制因子之间的失衡所致。血管内皮生长因子(VEGF)是一种关键的刺激因子,通过两种不同的酪氨酸激酶受体:VEGF-R1和VEGF-R2发挥生物学效应。可溶性形式的sVEGF-R1是VEGF活性的负调节因子。采用酶联免疫吸附测定(ELISA)法检测了24例非小细胞肺癌(NSCLC)患者、13例小细胞肺癌(SCLC)患者及10名健康志愿者血清中VEGF、sVEGF-R1的浓度。患者血清VEGF浓度显著高于对照组(p = 0.016)。患者与对照组sVEGF-R1浓度无显著差异。在VEGF和sVEGF-R1浓度方面,就以下临床特征而言未发现统计学显著差异:体能状态分期、临床分期(Ⅲ期与Ⅳ期)和组织学类型(NSCLC与SCLC)。直径大于7.5 cm的肿瘤患者VEGF浓度显著更高(p = 0.027)。分析治疗反应对所检测参数浓度影响时发现,疾病进展时VEGF浓度显著升高(p = 0.034)。治疗后sVEGF-R1浓度未改变。所检测参数之间未发现相关性。

相似文献

1
[Circulating VEGF and its soluble receptor sVEGFR-1 in patients with lung cancer].肺癌患者循环血管内皮生长因子及其可溶性受体sVEGFR-1
Pneumonol Alergol Pol. 2004;72(9-10):389-94.
2
Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.肺癌患者化疗期间血清中VEGF-C、VEGF-D和sVEGF-R2的水平。
Oncol Res. 2007;16(9):445-51.
3
Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.急性白血病患者循环中的血管内皮生长因子(VEGF)及其可溶性受体sVEGFR - 1和sVEGFR - 2 。
Eur Cytokine Netw. 2003 Jul-Sep;14(3):149-53.
4
Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations.银屑病治疗对 VEGF 及其可溶性受体血清浓度的影响。
J Eur Acad Dermatol Venereol. 2012 Mar;26(3):302-7. doi: 10.1111/j.1468-3083.2011.04053.x. Epub 2011 Mar 21.
5
Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: possible association with hepatic function impairment.肝硬化患者循环血管内皮生长因子及其可溶性受体:与肝功能损害的可能关联。
Cytokine. 2008 Oct;44(1):14-7. doi: 10.1016/j.cyto.2008.06.002. Epub 2008 Jul 25.
6
Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales.银屑病活动对血清和斑块鳞屑中 VEGF 及其可溶性受体浓度的影响。
Cytokine. 2010 Dec;52(3):225-9. doi: 10.1016/j.cyto.2010.09.012. Epub 2010 Oct 25.
7
Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.晚期非小细胞肺癌患者血清血管内皮生长因子(VEGF)及bcl-2水平
Cancer Invest. 2006 Oct;24(6):576-80. doi: 10.1080/07357900600894781.
8
[The estimation of serum concentration of vascular endothelial growth factor in patients with non-small cell lung cancer].[非小细胞肺癌患者血清血管内皮生长因子浓度的测定]
Pol Merkur Lekarski. 2007 Jun;22(132):536-8.
9
Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.肺癌患者血清中白细胞介素-18(IL-18)和可溶性白细胞介素-2受体(sIL-2R)的水平
Rocz Akad Med Bialymst. 2004;49:246-51.
10
Functional significance of vascular endothelial growth factor and its receptor (receptor-1) in various lung cancer types.血管内皮生长因子及其受体(受体-1)在不同类型肺癌中的功能意义。
Clin Biochem. 2004 Sep;37(9):840-5. doi: 10.1016/j.clinbiochem.2004.03.012.

引用本文的文献

1
Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients.血管内皮生长因子及其可溶性受体VEGFR-1和VEGFR-2水平在小细胞肺癌患者血清中的预后及预测价值
Med Oncol. 2008;25(4):394-9. doi: 10.1007/s12032-008-9052-4. Epub 2008 Mar 4.